Monoclonal Antibodies Market Size | COVID-19 Impact Analysis | Forecast to 2026

The global monoclonal antibodies market is estimated to grow at a CAGR of 8.6% during the forecast period. An increasing number of trials for monoclonal antibodies for COVID-19 patients. For instance, in October 2020, Celltrion Group declared the introduction of its Phase III clinical trial investigating CT-P59. It is an anti-COVID-19 monoclonal antibody therapy candidate. The company estimates the enrolment of nearly 1,000 patients to assess population-based prophylaxis in contacts of SARS-CoV-2 infected patients. The prophylaxis post-exposure clinical trial will assess the safety and preventive effect of CT-P59 and whether CT-P59 can produce a counteracting antibody response for the prevention of virus from infecting human cells. 

To Request a Sample of our Report on Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/monoclonal-antibodies-market

Further, in August 2020, the National Institutes of Health (NIH) introduced a clinical trial that aims to test antibody therapy in hospitalized COVID-19 patients. Under the trial, COVID-19 patients at selected hospitals can volunteer in a clinical trial intended to test the efficacy and safety of an effective novel treatment for COVID-19. It is a Phase 3 randomized, controlled trial which is referred to as ACTIV-3, and as a master protocol. This is designed to test several diverse kinds of monoclonal antibody therapies. One of the major benefits of monoclonal antibody therapy is that it can particularly target the SARS-CoV-2 virus and this makes them more potential compared to other drugs.

Scope of the Global Monoclonal Antibodies Market

Market Coverage

·        Market number available for 2019-2026

·        Base year- 2019

·        Forecast period- 2020-2026

·        Segment Covered- By Source and Application

·        Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World

·        Competitive Landscape- Amgen Inc., Eli Lilly & Co., F- Hoffman La-Roche AG, Pfizer Inc., and Novartis AG

Recent Strategic Initiatives in the Global Monoclonal Antibodies Market

·        In December 2019, Mylan N.V. and Biocon Ltd. declared the US FDA launch of Ogivri (trastuzumab-dkst). It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer. 

·        In June 2018, Pfizer Inc. announced the approval of ZIRABEV (bevacizumab-bvzr) in the US. It is a biosimilar to Avastin (bevacizumab) which is indicated to treat five kinds of cancer, including locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, unresectable, metastatic renal cell carcinoma (RCC), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer.

(Get 15% Discount on Buying this Report)

A full Report of Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/monoclonal-antibodies-market

Global Monoclonal Antibodies Market-Segmentation

By Source

·        Murine

·        Chimeric

·        Human

·        Humanized

By Application

·        Cancer

·        Infectious Diseases

·        Auto-Immune Diseases

·        Inflammatory Diseases

·        Others

Global Monoclonal Antibodies Market– Segment by Region 

North America

·        United States

·        Canada

Europe

·        UK

·        Germany

·        Spain

·        France

·        Italy

·        Rest of Europe

Asia-Pacific

·                  India

·                  China

·                  Japan

·                  South Korea

·                  Rest of APAC

Rest of the World

·        Middle East & Africa 

·        Latin America 

Company Profiles

·        AbbVie, Inc.

·        Amgen, Inc.

·        AstraZeneca plc

·        Aytu BioScience, Inc.

·        Bayer AG

·        Biocon, Ltd.

·        Biogen, Inc.

·        Bristol Myers Squibb Co.

·        Cadila Pharmaceuticals, Ltd.

·        Daiichi Sankyo Company, Ltd.

·        Dr. Reddy's Laboratories, Inc.

·        Eli Lilly and Co.

·        F. Hoffmann-La Roche AG

·        Genmab A/S

·        Gilead Sciences, Inc.

·        GlaxoSmithKline plc

·        Innate Pharma S.A.

·        ntas Biopharmaceuticals, Ltd.

·        Johnson & Johnson Services, Inc.

·        Lupin, Ltd.

·        Merck & Co., Inc.

·        Mylan N.V.

·        Novartis AG

·        Oncologie, Inc.

·        Orchard Therapeutics plc 

·        Pfizer, Inc.

·        Sanofi S.A.

·        Spectrum Pharmaceuticals, Inc.

·        Sun Pharmaceutical Industries, Ltd.

·        Takeda Pharmaceutical Co., Ltd.

Reasons to buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/monoclonal-antibodies-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

Comments

Post a Comment

Popular posts from this blog

European Data Backup and Recovery Market Size, Share, Analysis, Industry Report and Forecast 2019-2025

  European Data Backup and Recovery Market are expected to reach $5.7 billion in 2027, growing at a CAGR of 9.5% during the forecast period (2021-2027). Factors responsible for the growth of the market in Europe are well-developed telecommunication infrastructure, high internet penetration, high adoption of cloud-based devices among people and organization. Regulations regarding the data localization such as GDPR by the European Union and countries own data localization and protection act are providing growth to the market. Major economies which are expected to hold a considerable market are UK, Germany, France, Italy, and Spain. These economies are part of the European Union, which covers most of the continent. The aim of the European Union was to increase economic cooperation and encourage free trade among countries. To Request a Sample of our Report on European Data Backup and Recovery Market :   https://www.omrglobal.com/request-sample/european-data-backup-recovery-...
Read more

Insect Repellent Market Is Likely to Experience a Tremendous Growth by 2031

This informative Insect Repellent Market report provides new method and covers foremost regions such as Latin America, Middle East, North America, Europe, Africa and Asia Pacific. Making most out of the consumer insights and market opportunities, market players can boost up the revenue rate of their business. It also permits key organizations to make communication with customers and know their demands for making right investment in the product development. By increasing the product portfolio by referring the important market data provided in this Insect Repellent Market research report, key players can grow and expand their business forward. Continuously developing customer demands are also described in this global report to help new entrants make required changes in the final product launch and then bring into the market. It becomes easy for key players to prioritize the demands and requirements of target audience and have complete understanding of end-user experience with the help o...
Read more

Asia-Pacific Urban Air Mobility Market Growth, Size, Share, Industry Report and Forecast 2019-2025

The Asia-Pacific urban air mobility market is estimated to grow at a CAGR of 12.6% during the forecast period. The Asia-Pacific urban air mobility market is segmented on the basis of component and operation. Based on the component, the market is further segmented into infrastructure and platform. The infrastructure segment is further segmented into charging stations, traffic management, and others whereas, the platform segment is further classified into air taxi, personal air vehicle, air ambulance, and others. The platform segment dominated the global urban air mobility market. To Request a Sample of our Report on Asia-Pacific Urban Air Mobility Market :   https://www.omrglobal.com/request-sample/asia-pacific-urban-air-mobility-market Asia-Pacific is home to several emerging economies and is seen as the potential market for the UAM owing to growing urbanization coupled with increasing traffic congestion and increasing high-income groups in the region. The growth of the As...
Read more